GRK4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3761722	1.00	3/20
SCHEMBL3761756	1.00	3/20
SCHEMBL3761689	0.73	3/20
SCHEMBL3756415	0.73	3/20
SCHEMBL3756906	0.70	3/20
SCHEMBL3760419	0.70	3/20
Trifluoroacetic Acid (SCHEMBL3756875)	0.69	3/20
SCHEMBL3758760	0.68	3/20
SCHEMBL3762687	0.68	3/20
SCHEMBL3756630	0.67	3/20
SCHEMBL3761735	0.67	3/20
SCHEMBL3761908	0.67	3/20
SCHEMBL3758740	0.64	3/20
SCHEMBL3762572	0.64	3/20
SCHEMBL3756877	0.63	3/20
SCHEMBL3763607	0.63	3/20
SCHEMBL3756874	0.62	3/20
SCHEMBL3756682	0.59	3/20
SCHEMBL3756618	0.58	3/20
SCHEMBL3762587	0.57	3/20

Clinical trials — most relevant to GRK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
GRK4 Polymorphisms Blood Pressure Response to Candesartan	PHASE4	UNKNOWN
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma	PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer	PHASE1	RECRUITING
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction	nan	COMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome	nan	ACTIVE_NOT_RECRUITING
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People	nan	COMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
Study of Adrenal Gland Tumors	nan	COMPLETED
Effect of Symbicort on GR Localisation in Asthma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRK4 binder may also engage these)

Protein	Name	Similarity
O70291	—	0.998	O70291 →
Q62833	—	0.997	Q62833 →
GRK5	G protein-coupled receptor kinase 5	0.996	landscape →
P43249	—	0.996	P43249 →
P70507	—	0.994	P70507 →
Q8VEB1	—	0.990	Q8VEB1 →
P97711	—	0.983	P97711 →
GRK6	G protein-coupled receptor kinase 6	0.981	landscape →
O70293	—	0.981	O70293 →
Q8K1Y2	—	0.970	Q8K1Y2 →
Q8BWW9	—	0.969	Q8BWW9 →
Q5XIS9	—	0.968	Q5XIS9 →
PRKD1	Serine/threonine-protein kinase D1	0.966	landscape →
A0A8I5ZNK2	—	0.964	A0A8I5ZNK2 →
MAPK8	Mitogen-activated protein kinase 8	0.963	landscape →
Q6NYU2	—	0.963	Q6NYU2 →
Q90327	—	0.962	Q90327 →
Q6P9R2	—	0.962	Q6P9R2 →
Q91604	—	0.962	Q91604 →
Q8AYC9	—	0.962	Q8AYC9 →
PRKD2	Serine/threonine-protein kinase D2	0.962	landscape →
A7MBL8	—	0.962	A7MBL8 →
Q3UMW7	—	0.962	Q3UMW7 →
O94844	—	0.962	O94844 →
PKN2	Serine/threonine-protein kinase N2	0.961	landscape →
Q863I2	—	0.961	Q863I2 →
Q9BYZ6	—	0.961	Q9BYZ6 →
Q6ZI44	—	0.961	Q6ZI44 →
P47197	—	0.960	P47197 →
Q8QHK8	—	0.960	Q8QHK8 →